Swarm Learning for decentralized and confidential clinical machine learningStefanie Warnat‐Herresthal, Susanne Isfort, Hartmut Schultze et al.|Nature|2021Cited by 833
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersPeter Horak, Klaus Schulze‐Osthoff, Dorothea Hanf et al.|Cancer Discovery|2021Cited by 282
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancerJan Harder, Michael Geißler, Gabriele Ihorst et al.|British Journal of Cancer|2012Cited by 184
Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.Milind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|Journal of Clinical Oncology|2021Cited by 86